Tysabri Progressive Multifocal Leukoencephalopathy Attorney: Statute of Limitations for Tysabri in Pennsylvania

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Occupational Exposure Concerns

The legacy domain of general health and science information has long served as a foundational resource for public understanding of medical conditions and therapeutic options. Within this context, structured data from clinical trial registries and regulatory databases have provided transparent insights into drug development and safety profiles. As the focus narrows from broad health literacy to specific occupational and legal concerns, a natural pivot emerges around the real-world implications of pharmaceutical exposure. In mass production environments, workers may handle or be exposed to biologic agents such as Tysabri, a medication used in certain chronic conditions. The transition from general awareness to occupational exposure concern involves recognizing that individuals in manufacturing, laboratory, or clinical settings could face unintended contact with such substances. This shift requires attention to the potential long-term health consequences, including the risk of progressive multifocal leukoencephalopathy, a serious condition associated with immunosuppressive therapies. For those affected, understanding the legal framework—such as the statute of limitations for filing claims in Pennsylvania—becomes critical. Thus, the legacy of accessible health data now serves a new purpose: informing workers and their advocates about exposure risks and the time-sensitive nature of seeking legal recourse.

Find Out If You Qualify for Compensation →

Tysabri and the Risk of Progressive Multifocal Leukoencephalopathy

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its prescribing information includes a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, and the label identifies three risk factors: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first indication of the condition (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML can be variable, but common symptoms include progressive neurological deficits such as weakness, gait disturbance, cognitive impairment, and visual changes. These symptoms overlap with those reported in adverse-event databases for Tysabri. For example, FDA FAERS data list fatigue (19,150 reports), multiple sclerosis relapse (16,691 reports), gait disturbance (9,422 reports), memory impairment (7,895 reports), and cognitive disorder (3,478 reports) among the most frequent adverse events associated with the drug (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not confirm causation, they highlight the importance of distinguishing PML from multiple sclerosis relapse or other neurological conditions.

Mechanism of PML and Legal Implications for Pennsylvania Patients

The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. By blocking the adhesion molecule VLA-4, Tysabri inhibits lymphocyte migration across the blood-brain barrier. This immunosuppressive effect in the central nervous system can allow latent JC virus to reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the characteristic lesions of PML. The risk is highest in patients with anti-JCV antibodies, as these antibodies indicate prior exposure to the virus. Duration of therapy beyond two years further increases risk, likely due to prolonged CNS immunosuppression. For patients in Pennsylvania who have developed PML after Tysabri treatment, legal considerations include the statute of limitations for filing a product liability claim. In Pennsylvania, the statute of limitations for personal injury actions is generally two years from the date the injury was discovered or reasonably should have been discovered. For PML, the date of discovery may be the date of diagnosis via MRI or cerebrospinal fluid PCR testing. However, the timeline between Tysabri exposure and documented harm can be prolonged. PML may develop months to years after starting treatment, and symptoms may initially be subtle, delaying diagnosis. This latency period can complicate the determination of when the statute of limitations begins to run. Adequacy of warnings is a central issue in potential litigation. The Tysabri label includes a boxed warning and requires enrollment in the TOUCH Prescribing Program, which mandates that patients read a Medication Guide and understand the risks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, questions may arise about whether healthcare providers adequately communicated the specific risk factors—such as anti-JCV antibody status and treatment duration—to patients. The label states that risk factors should be considered in the context of expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). If a patient was not informed of their anti-JCV antibody status or the increased risk after two years of therapy, the adequacy of the warning may be challenged. Attorney-related considerations for affected patients include the need to preserve medical records documenting Tysabri administration dates, anti-JCV antibody test results, and the timeline of PML diagnosis. Expert testimony from neurologists and infectious disease specialists may be required to establish the causal link between Tysabri and PML in a specific case. The FAERS data provide a population-level signal but are not sufficient to prove individual causation. Plaintiffs must demonstrate that the drug was a substantial factor in causing the injury. In summary, Tysabri carries a well-documented risk of PML, with specific risk factors that should guide clinical decision-making. For Pennsylvania patients who have suffered PML, the statute of limitations is a critical factor that depends on the date of diagnosis. Legal claims may focus on the adequacy of warnings provided to patients and whether healthcare providers followed label recommendations for risk assessment and monitoring.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Pennsylvania?

In Pennsylvania, the statute of limitations for personal injury actions is generally two years from the date the injury was discovered or reasonably should have been discovered. For PML, this is typically the date of diagnosis via MRI or cerebrospinal fluid PCR testing. However, due to the latency period between Tysabri exposure and PML onset, the exact start date may be contested. It is crucial to consult with an attorney promptly to preserve your rights.

What evidence is needed to prove a Tysabri-PML link in a legal claim?

To establish causation, plaintiffs need medical records documenting Tysabri administration dates, anti-JCV antibody test results, and the timeline of PML diagnosis. Expert testimony from neurologists and infectious disease specialists is often required to demonstrate that Tysabri was a substantial factor in causing PML. While FDA FAERS data show a population-level signal, individual proof is necessary.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.